RECURRENT CHRONIC BACTERIAL PROSTATITIS IN ELDERLY PATIENTS AND OLDER: DIAGNOSTICS. SELECTION OF ADEQUATE THERAPY

H.N. Dzhalilov; T.V. Tsarueva; D.N. Dzhalilova; A.S. Mugudinova; A.M. Magomedova; A.M. Kasumova; Sh.Sh. Radjabova

doi:10.34921/amj.2021.3.004

Authors

H.N. Dzhalilov Federal State Budgetary Administration of Higher Education "Dagestan State Medical University" of the Ministry of Health of the Russian Federation
T.V. Tsarueva Federal State Budgetary Administration of Higher Education "Dagestan State Medical University" of the Ministry of Health of the Russian Federation
D.N. Dzhalilova Federal State Budgetary Administration of Higher Education "Dagestan State Medical University" of the Ministry of Health of the Russian Federation
A.S. Mugudinova Federal State Budgetary Administration of Higher Education "Dagestan State Medical University" of the Ministry of Health of the Russian Federation
A.M. Magomedova Federal State Budgetary Administration of Higher Education "Dagestan State Medical University" of the Ministry of Health of the Russian Federation
A.M. Kasumova Federal State Budgetary Administration of Higher Education "Dagestan State Medical University" of the Ministry of Health of the Russian Federation
Sh.Sh. Radjabova Federal State Budgetary Administration of Higher Education "Dagestan State Medical University" of the Ministry of Health of the Russian Federation

DOI:

https://doi.org/10.34921/amj.2021.3.004

Keywords:

prostatitis, levofloxacin, polyoxidonium, wobenzym

Abstract

The study assesses the effectiveness of complex and standard treatment of elderly and older patients with recurrent chronic bacterial prostatitis. The complex therapy included a new generation fluoroquinolone levofloxacin (tavanic), an immunomodulator polyoxidonium and an enzyme wobenzym. A prospective comparative study was carried out, which included 102 patients with a diagnosis of recurrent chronic bacterial prostatitis. 51 patients (comparison group) received standard etiopathogenetic therapy, and patients of the main group (51 people) additionally received the immunomodulator polyoxidonium and the polyenzyme wobenzym.

At the third visit after 3 months, it was found that the clinical and microbiological effectiveness of complex therapy was almost 2 times higher than in patients in the comparison group (72.4% and 35.7%, respectively). the main group (51 people) - additionally took the immunomodulator polyoxidonium and the polyenzyme wobenzym.

Comparative evaluation of the therapy showed that in patients of the comparison group, the parameters of the number of leukocytes in the secretion of the prostate and the 3rd portion of urine were significantly higher than in patients who received complex therapy. The inclusion in the complex therapy of the immunomodulator polyoxidonium and the polyenzyme wobenzym contributed to the improvement of impaired urination, reduction of pain syndrome, and the quality of life (Qol) improved and averaged up to 3.8 points (and in the comparison group up to 7.2 points). As a result of the complex therapy, the relapses of the disease also decreased in the patients of the main group.